Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06092281
Other study ID # KY20232292-F-1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2023
Est. completion date December 2029

Study information

Verified date January 2024
Source Xijing Hospital of Digestive Diseases
Contact Zhiguo Liu
Phone 86-29-84771535
Email liuzhiguo@fmmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Endoscopic submucosal dissection (ESD) is now considered the standard treatment for early gastrointestinal neoplasms. However, there is still a possibility of developing local recurrence or metachronous neoplasia after ESD. Regular endoscopic surveillance after ESD can identify and remove local recurrences and metachronous lesions early, improving patient prognosis. However, the patient compliance with post-ESD endoscopic surveillance is currently unclear, and many patients fail to adhere to the scheduled follow-up. A prospective, randomized controlled, superiority trial was designed to evaluate whether completing a questionnaire and receiving feedback on compliance-related education can improve patient compliance with post-ESD endoscopic surveillance, in comparison to those who did not complete the compliance-related education questionnaire. Additionally, the investigators intend to investigate the factors that influence patient compliance. This study will consist of two parts. Part 1 will assess whether the completion of questionnaire and feedback on compliance-related education can improve short-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing short-term patient compliance. Part 2 will assess whether the completion of questionnaire and feedback on compliance-related education can improve long-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing patient compliance.


Description:

This is a prospective, randomized controlled, superiority trial. The study population consists of patients after ESD for mucosal lesions at Xijing Hospital. In the control arm, patients after ESD are informed on follow-up instructions by doctors about the follow-up requirements before discharge, and complete a questionnaire without compliance-related education. In the questionnaire arm, in addition to receiving the same follow-up instructions as the control arm, patients need to complete a questionnaire on compliance-related education before discharge. Based on the responses, nurses provide feedback and guidance. Patients and doctors will be blind to the group of patients during the trial process. Our objective is to evaluate whether completing a questionnaire and receiving feedback on compliance-related education can improve patient compliance with post-ESD endoscopic surveillance, in comparison to those who did not complete the compliance-related education questionnaire. Additionally, the investigators intend to investigate the factors that influence patient compliance. Part 1 will assess whether the completion of questionnaire and feedback on compliance-related education can improve short-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing short-term patient compliance. Part 1 will be expected to include 220 post-ESD patients randomized 1:1 into the questionnaire arm and control arm. Sample size calculation is based on short-term compliance data from a pilot trial, with a 20% difference between the two groups. Under the conditions of an α error of 5% (in a one-sided test) and power of 80%, assuming a superiority margin of 5%, a sample size of 220 cases is required. Part 2 will assess whether the completion of questionnaire and feedback on compliance-related education can improve long-term patient compliance with post-ESD endoscopic surveillance, and investigate factors influencing patient compliance. Part 2 will be expected to include 500 post-ESD patients randomized 1:1 into the questionnaire arm and control arm. Under the conditions of an α error of 5% (in a one-sided test) and power of 80%, assuming a 20% difference between the two groups in long-term compliance outcome, a superiority margin of 10%, and rounding up, a sample size of 500 cases is required.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 2029
Est. primary completion date December 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Adult patients (=18 years) after ESD for mucosal lesions. Exclusion Criteria: - Patients after ESD for submucosal tumors, e.g. stromal tumors, neuroendocrine tumors; - Additional radical surgery after ESD procedure; - Past history of ESD procedure or local recurrence; - Severe comorbidities with a life expectancy of <6 months as judged by the investigator; - Unable to cooperate with information collection due to mental disorders, severe neurosis, or dysgnosia; - Unable to understand or unwilling to sign a written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaire
Patients after ESD need to complete a questionnaire on compliance-related education before discharge. The questionnaire includes the following information: General information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.) Awareness of follow-up examinations (e.g., knowledge about the timing of the first follow-up, the process of follow-up examinations, related educational issues about follow-up, etc.) Awareness of the disease (self-perceived tumor is benign or malignant, whether lifestyle changes are required, etc.)
Questionnaire without compliance-related education
Patients after ESD need to complete a questionnaire without compliance-related education before discharge. The questionnaire includes only general information about the patient (e.g., education level, place of residence, economic status, employment status, family history of neoplasms, whether the patient or immediate family member has a medical background, number of previous endoscopic examinations, etc.)

Locations

Country Name City State
China Xijing Hospital of Digestive Disease Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital of Digestive Diseases

Country where clinical trial is conducted

China, 

References & Publications (4)

Ishihara R, Arima M, Iizuka T, Oyama T, Katada C, Kato M, Goda K, Goto O, Tanaka K, Yano T, Yoshinaga S, Muto M, Kawakubo H, Fujishiro M, Yoshida M, Fujimoto K, Tajiri H, Inoue H; Japan Gastroenterological Endoscopy Society Guidelines Committee of ESD/EMR for Esophageal Cancer. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc. 2020 May;32(4):452-493. doi: 10.1111/den.13654. — View Citation

Ono H, Yao K, Fujishiro M, Oda I, Uedo N, Nimura S, Yahagi N, Iishi H, Oka M, Ajioka Y, Fujimoto K. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021 Jan;33(1):4-20. doi: 10.1111/den.13883. Epub 2020 Dec 9. — View Citation

Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, Lemmers A, Maselli R, Messmann H, Pech O, Pioche M, Vieth M, Weusten BLAM, van Hooft JE, Deprez PH, Dinis-Ribeiro M. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022 Jun;54(6):591-622. doi: 10.1055/a-1811-7025. Epub 2022 May 6. — View Citation

Tanaka S, Kashida H, Saito Y, Yahagi N, Yamano H, Saito S, Hisabe T, Yao T, Watanabe M, Yoshida M, Saitoh Y, Tsuruta O, Sugihara KI, Igarashi M, Toyonaga T, Ajioka Y, Kusunoki M, Koike K, Fujimoto K, Tajiri H. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc. 2020 Jan;32(2):219-239. doi: 10.1111/den.13545. Epub 2019 Dec 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: short-term endoscopic surveillance compliance Patients who undergo their first endoscopic surveillance within 3 months after ESD are considered to have good compliance, otherwise they are considered to have poor compliance. From enrollment to the end of the first endoscopic surveillance (3 months)
Primary Part 2: long-term endoscopic surveillance compliance The criteria for endoscopic surveillance after ESD in this study are as follows: (1) For patients with non-neoplastic lesions and benign tumors after ESD, a follow-up of at least 1 year is required; (2) For patients with low-grade intraepithelial neoplasia and adenoma after ESD, a follow-up of at least 1 year is required; (3) For patients with high-grade intraepithelial neoplasia, a follow-up of at least 3 years is required, with an interval not exceeding 2 years; (4) For patients with carcinoma, a follow-up of at least 5 years is required, with an interval not exceeding 2 years. The criteria for assessing the compliance of endoscopic surveillance in this study are as follows: Patients who undergo endoscopic surveillance according to the above-mentioned criteria are considered to have good compliance, otherwise they are considered to have poor compliance. From enrollment to the end of the last endoscopic surveillance (1-5 years)
Secondary Part 1: Ulcer scar rate Percentage of people with ulcer scar stage at first endoscopic surveillance after ESD. The investigators will evaluate ulcer scar rates using a gastric ulcer staging system and measure the ulcer size. From enrollment to the end of the first endoscopic surveillance (3 months)
Secondary Part 1: Correlated Factors for short-term endoscopic surveillance compliance The short-term endoscopic surveillance compliance may be influenced by other factors. Patients who undergo their first endoscopic surveillance within 3 months after ESD are considered to have good compliance, otherwise they are considered to have poor compliance. First, univariate analysis will be used to identify potential factors influencing short-term endoscopic surveillance compliance. Then, all possible factors will be included in multivariate analysis. From enrollment to the end of the first endoscopic surveillance (3 months)
Secondary Part 2: Incidence of metachronous lesions Metachronous lesions are defined as lesions diagnosed at a minimum interval of 6 months after the initial neoplasia, and the location and pathological type of the lesion are different from the initial neoplasia. Up to 5 years
Secondary Part 2: Incidence of local recurrence Percentage of patients with local recurrence detected during follow-up Up to 5 years
Secondary Part 2: Overall survival rate Percentage of people still alive at 5 years after ESD 5 years
Secondary Part 2: Correlated Factors for long-term endoscopic surveillance compliance The long-term endoscopic surveillance compliance may be influenced by other factors. Patients who undergo endoscopic surveillance according to the above-mentioned criteria (see Outcome 2) are considered to have good compliance, otherwise they are considered to have poor compliance. First, univariate analysis will be used to identify potential factors influencing long-term endoscopic surveillance compliance. Then, all possible factors will be included in multivariate analysis. From enrollment to the end of the last endoscopic surveillance (1-5 years)
See also
  Status Clinical Trial Phase
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Completed NCT05297188 - The Effect of Ergonomic Sleep Mask Usage on Patients' Sleep Quality and Comfort
Completed NCT03264937 - Social-software iMproving wARfarin Therapy N/A
Completed NCT04291807 - Video Assisted Education Before ERCP N/A
Completed NCT02742740 - Study Buddy (an ECA Oncology Trial Advisor) for Cancer Trials N/A
Completed NCT03220204 - Researching Emotions And Cardiac Health: Phase III N/A
Completed NCT02756949 - Smart Linkage-to-HIV Care Via a Smartphone App N/A
Completed NCT02669355 - Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting N/A
Completed NCT03147716 - Parent Engagement Package: Comparing Strategies for Engaging Parents Into Parenting Programs N/A
Completed NCT01568515 - Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students Phase 0
Completed NCT03125668 - Impact of Telephone Follow-up in Patient's Health-related Quality of Life That Use Warfarin N/A
Recruiting NCT03753035 - Observance of Anticonvulsant Treatments and Quality of Life of Epileptic Children
Completed NCT05331820 - The Influence of Weekly Reminders on Enhancing Patient Compliance in Patients With Fixed Orthodontic Treatment N/A
Completed NCT02294019 - Actual Use Trial of Ibuprofen 400 mg Phase 3
Not yet recruiting NCT02301923 - Continuous Positive Airway Pressure (CPAP) Compliance in Obstructive Sleep Apnea N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT01752595 - The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment N/A
Completed NCT01559805 - Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men N/A
Active, not recruiting NCT01454830 - Tailored Intervention to Promote Positive Airway Pressure Adherence Phase 1
Completed NCT01174706 - Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients N/A